Federal and state investigators have launched a broad inquiry into Epic Systems Corp., examining whether the electronic health record vendor has engaged in anticompetitive business practices, according to a report published by STAT News. The scrutiny focuses on the Wisconsin-based software developer, whose infrastructure manages medical records for a large share of hospitalized Americans. While the investigation remains in its early stages and has not resulted in formal charges, it brings attention to the company’s business practices.
Epic Systems holds a dominant market position. Because electronic health records serve as the operating system of a modern hospital, switching providers involves enormous costs: years of implementation, retraining of clinicians, and migration of decades of patient data. This stickiness is the source of the market power that antitrust enforcers look for. Authorities investigate specific behavior—analyzing if a leading corporation deploys pricing strategies, contractual agreements, or technical limitations to block competitors from reaching potential buyers.
According to reporting from STAT News, investigators have contacted individuals working within or advising healthcare businesses that interface directly with Epic. These sources indicated that questioning spanned a wide variety of company policies and practices, including the use of non-disclosure agreements. Regulators examine contract language if they believe it suppresses the flow of information customers and competitors would need to shop, complain or benchmark.
Regulatory Scrutiny of Private Health IT Vendors
Because Epic Systems is a privately held corporation, it lacks the public disclosures, stock tickers, and mandatory quarterly earnings calls that typically bring transparency to publicly traded technology firms. Consequently, an antitrust inquiry into the company functions differently than standard corporate investigations, with its immediate practical impacts falling primarily on competing health IT vendors, analytics firms, and independent application developers.
The Federal Trade Commission operates under Section 5 of the Federal Trade Commission Act, which prohibits “unfair methods of competition” and “unfair or deceptive acts or practices.” According to the Federal Trade Commission, antitrust enforcement generally targets two primary categories of conduct: horizontal conduct involving agreements between direct competitors, and single-firm conduct involving monopolization or attempts to maintain a dominant market position through unreasonable exclusionary methods. Authorities point out that possessing a monopoly or setting “high prices” is not inherently unlawful; instead, a firm breaches regulations only when it attempts to build or preserve its monopoly status through improper tactics.
Key Conduct Areas Under Examination
In the health technology sector, antitrust inquiries typically focus on specific operational bottlenecks that can restrict market access for smaller rivals. Investigations often center on three critical pillars:
- Interoperability and Data Access: Regulators evaluate whether third-party developers can read from and write to the record on commercially reasonable terms, or if access is throttled, delayed, or priced in a way that favors the incumbent’s own modules.
- Integration Restrictions: Assessors review whether independent software developers can link into the medical records without accepting conditions that restrict their competitive capabilities.
- Contractual Terms: The use of restrictive non-disclosure agreements is a focal point, with enforcers examining whether such clauses limit transparency and hinder market evaluation.
As detailed by Biotech Insider, an active antitrust inquiry can produce significant near-term behavioral shifts even before reaching a legal conclusion. Corporations facing active scrutiny frequently soften their stances on peripheral matters—speeding up interface integration, showing greater flexibility in contract terms, and reducing aggressive bundling practices.
Broader Regulatory Context and Next Steps
The current antitrust probe operates alongside federal information-blocking rules, which obligate health IT developers to share electronic health information except in defined circumstances. The convergence of antitrust oversight and information-blocking regulations raises the stakes on the same conduct from two directions.
Because inquiries represent a fact-finding stage rather than a formal accusation, the timeline from investigation to resolution can span several years. Outcomes can range entirely from a closed file to a consent order or litigation. For hospital chief information officers negotiating renewals, the proceedings offer visibility into the commercial terms of a market that has been largely opaque.
Worth a look